You're viewing a public preview of Dogma's Oral PCSK9 Inhibitor Program Sign up free to access full investment history, financials, executives & more
Sign Up Free Log In

Dogma's Oral PCSK9 Inhibitor Program

Inactive
Boxford,  Massachusetts (MA),  United States
Sector: Life Science Entity: Private
Merged Dogma's Oral PCSK9 Inhibitor Program merged into AstraZeneca plc in 2020
2
Transactions
Sign up to view
About Dogma's Oral PCSK9 Inhibitor Program
Available information shows that Dogma's Oral PCSK9 Inhibitor Program operates in the Life Science sector. Investors on record include AstraZeneca plc. The company is headquartered in Boxford, Massachusetts (MA). This profile is documented within AcquityData.
Investors
Current Investors
AstraZeneca plc ••••••••
Past Investors
•••••••• ••••••••
View Full Investor List
Sign up to see all current & past investors with deal dates and transaction details
Sign Up Free Log In
Investment Details
2 Transactions
Trans. IDInvestment DateExit DateInvestor(s)Deal Size (M)Seller(s)
Access 2 Transactions
Sign up to view the full investment history — dates, deal sizes, investors & sellers
Sign Up Free Log In
Dogma's Oral PCSK9 Inhibitor Program M&A Activity
# Company Transaction Date Close Date Sector Country
View M&A Acquisitions
Sign up to explore the full acquisition & merger history
Sign Up Free Log In
Key Executives & Professionals
View Executives & Professionals
Sign up to access board members, senior management & key contacts
Sign Up Free Log In
Frequently Asked Questions
What does Dogma's Oral PCSK9 Inhibitor Program do?
Available information shows that Dogma's Oral PCSK9 Inhibitor Program operates in the Life Science sector. Investors on record include AstraZeneca plc. The company is headquartered in Boxford, Massachusetts (MA). This profile is documented within AcquityData.
Where is Dogma's Oral PCSK9 Inhibitor Program headquartered?
Dogma's Oral PCSK9 Inhibitor Program is headquartered in Boxford, Massachusetts (MA), United States.
When was Dogma's Oral PCSK9 Inhibitor Program founded?
Founded year information for Dogma's Oral PCSK9 Inhibitor Program is available on AcquityData.
What sector is Dogma's Oral PCSK9 Inhibitor Program in?
Dogma's Oral PCSK9 Inhibitor Program operates in the Life Science sector.
Who are the investors in Dogma's Oral PCSK9 Inhibitor Program?
Current investors in Dogma's Oral PCSK9 Inhibitor Program include AstraZeneca plc. Sign up to AcquityData to view full investor details, deal dates and transaction history.
How many M&A transactions has Dogma's Oral PCSK9 Inhibitor Program been involved in?
Dogma's Oral PCSK9 Inhibitor Program has 2 transactions tracked on AcquityData. Sign up to view full investment history including dates, deal sizes, investors and sellers.

Unlock the full Dogma's Oral PCSK9 Inhibitor Program profile

Ownership & Investors M&A History Financials Key Executives Advisors & Lenders

Access Dogma's Oral PCSK9 Inhibitor Program's complete ownership history, M&A activity, investors, advisors and executives in one connected platform.

Start Free Trial